OncoMed Pharmaceuticals’ Dr Jakob Dupont has resigned as senior vice president and chief medical officer, and is due to step down from 1 January 2017.
Dr Dupont first joined the California-based oncology specialist in 2011, having moved from Roche where he was global medical director of Avastin.
Prior to this, Dr Dupont was director of early and late stage development at Genentech, and served as a researcher in tumour immunology at the Memorial Sloan Kettering Cancer Center.
Paul Hastings, OncoMed’s chairman and chief executive officer, said: “It is with great sadness that we announce Jakob’s resignation.
“During his five-year tenure, Jakob has built an impressive clinical development team that is advancing seven novel anti-cancer investigational drugs in the clinic, including earlier this year, completion of enrollment in our YOSEMITE and PINNACLE randomized phase II trials.
“Although we regret Jakob’s departure, we respect his decision and wish him all the best, and thank him for his many significant contributions to the company.”